Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Biophytis ( (BPTSY) ) has provided an update.
On January 21, 2025, Biophytis SA announced a co-development agreement with AskHelpU, China’s largest ALS patient association, to evaluate the efficacy of their lead drug candidate, BIO101, in treating amyotrophic lateral sclerosis (ALS). This partnership will leverage Biophytis’ expertise in drug development and AskHelpU’s extensive network and knowledge of ALS, potentially advancing BIO101 towards larger-scale clinical trials if initial results are promising. This agreement represents a significant opportunity for Biophytis to expand the therapeutic applications of BIO101, highlighting its potential in treating rare neuromuscular diseases and strengthening its position in the biotechnology industry.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Its lead drug candidate, BIO101, is a small molecule in development for muscular diseases, respiratory diseases, and metabolic disorders. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. Biophytis’ shares are listed on Euronext Growth Paris and its ADS are listed on the OTC market.
YTD Price Performance: -24.62%
Average Trading Volume: 3
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.65M
For an in-depth examination of BPTSY stock, go to TipRanks’ Stock Analysis page.